Graft rejection following HLA matched T‐lymphocyte depleted bone marrow transplantation

Patterson, J.; Prentice, HG; Brenner, Malcolm K.; Gilmore, M. J. M. L.; Jánossy, G.; Ivory, Kamal; Skeggs, D.; Morgan, H.Y.; Lord, J.; Blacklock, Hilary; Hoffbrand, A. V.; Apperley, Jane F.; Goldman, John M.; Burnett, AK; Gribben, JG; Alcorn, M.; Pearson, C.; Mcvickei, I.; Hann, Ian; Reid, C. D. L.; Wardle, D.; Gravett, Peter; Bacigalupo, Almalina; Robertson, A. A.

doi:10.1111/j.1365-2141.1986.tb05544.x

Cited by 154 publications

(17 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It can be prevented by selected methods, but often at the expense of an increased risk of relapse, rejection or delayed immune reconstitution. [1][2][3] Hence, no optimal or even satisfactory prevention and treatment method can be defined. To advance our knowledge and define optimal approaches, correct information on the value of different strategies and methods in GVHD prevention and treatment is essential.…”

Section: Introductionmentioning

confidence: 99%

Prophylaxis and treatment of GVHD: EBMT–ELN working group recommendations for a standardized practice

Ruutu

Gratwohl

Witte

et al. 2013

Bone Marrow Transplant

267

216

View full text Add to dashboard Cite

working group of the European Group for Blood and Marrow Transplantation (EBMT) and the European LeukemiaNet (ELN) GVHD remains the major impediment to broader application of allogeneic haematopoietic SCT. It can be prevented completely, but at the expense of other complications, rejection, relapse or delayed immune reconstitution. No optimal prevention or treatment method has been defined. This is reflected by enormous heterogeneity in approaches in Europe. Retrospective comparisons between different policies, although warranted, do not give definite answers. In order to improve the present situation, an European Group for Blood and Marrow Transplantation and the European LeukemiaNet working group has developed in a Delphilike approach recommendations for prophylaxis and treatment of GVHD in the most common allogeneic transplant setting, transplantation from an HLA-identical sibling or unrelated donor for standard risk malignant disease. The working group proposes these guidelines to be adopted as routine standard in transplantation centres and to be used as comparator in systematic studies evaluating the advantages and disadvantages of practices differing from these recommendations.

show abstract

Section: Introductionmentioning

confidence: 99%

Prophylaxis and treatment of GVHD: EBMT–ELN working group recommendations for a standardized practice

Ruutu

Gratwohl

Witte

et al. 2013

Bone Marrow Transplant

267

216

View full text Add to dashboard Cite

show abstract

“…Negative selection can be achieved either through physical methods such as counterflow elutriation [3,4,5] or soybean lectin agglutination (SBA) and sheep red blood cell (sRBC)-rosette depletion (E-rosetting) [6,7,8,9,10], or immunological methods using monoclonal antibodies [5,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29]. Monoclonal antibodies can be used with or without complement, or conjugated to toxins.…”

Section: T-cell Depletion Techniquesmentioning

confidence: 99%

Effects of T-Cell Depletion on Allogeneic Hematopoietic Stem Cell Transplantation Outcomes in AML Patients

Hobbs

Perales

2015

JCM

View full text Add to dashboard Cite

Graft versus host disease (GVHD) remains one of the leading causes of morbidity and mortality associated with conventional allogeneic hematopoietic stem cell transplantation (HCT). The use of T-cell depletion significantly reduces this complication. Recent prospective and retrospective data suggest that, in patients with AML in first complete remission, CD34+ selected grafts afford overall and relapse-free survival comparable to those observed in recipients of conventional grafts, while significantly decreasing GVHD. In addition, CD34+ selected grafts allow older patients, and those with medical comorbidities or with only HLA-mismatched donors to successfully undergo transplantation. Prospective data are needed to further define which groups of patients with AML are most likely to benefit from CD34+ selected grafts. Here we review the history of T-cell depletion in AML, and techniques used. We then summarize the contemporary literature using CD34+ selection in recipients of matched or partially mismatched donors (7/8 or 8/8 HLA-matched), and provide a summary of the risks and benefits of using T-cell depletion.

show abstract

“…Multiple animal and clinical studies have shown the dichotomous role of T cells in donor engraftment and GVHD [4,5,[11][12][13][14][15] . With recently available canine CD3 and CD5 antibodies, we have advanced our model to begin to adjust the donor graft for T-cell dosaging.…”

Section: Commentmentioning

confidence: 99%

Use of T-Cell Antibodies for Donor Dosaging in a Canine Model of in utero Hematopoietic Stem Cell Transplantation

Petersen¹,

Gendelman²,

Murphy³

et al. 2007

Fetal Diagn Ther

View full text Add to dashboard Cite

Aim: Microchimerism following canine in utero hematopoietic stem cell transplantation (IUHSCT) development of T-cell dosing regimens. Objective: To investigate the use of anti-T-cell antibodies for cell dosing of the donor graft in a canine model of IUHSCT. Study Design: Canine IUHSCT was performed by ultrasound-guided intraperitoneal injection in days 35–38 of fetal canines with CD34⁺ cells at doses of 4.5 × 10⁸ to 1.3 × 10⁹ cells/kg and T cells (CD3⁺ CD5⁺) at doses of 8 × 10⁶ to 8.8 × 10⁸ cells/kg. Postnatal studies included tissue histology and polymerase chain reaction-based chimerism analysis. Results: Term survival was 86–100%. Microchimerism (0–2%) was detected in five of eight recipients in multiple tissues. Histopathology revealed no evidence of graft-versus-host disease (GVHD). Conclusion: Canine IUHSCT is a useful model to investigate the role of donor T cells in engraftment and GVHD. IUHSCT at early gestational ages with high doses of donor T cells in the graft yields microchimerism in multiple tissues without GVHD.

show abstract

Graft rejection following HLA matched T‐lymphocyte depleted bone marrow transplantation

Cited by 154 publications

References 24 publications

Prophylaxis and treatment of GVHD: EBMT–ELN working group recommendations for a standardized practice

Prophylaxis and treatment of GVHD: EBMT–ELN working group recommendations for a standardized practice

Effects of T-Cell Depletion on Allogeneic Hematopoietic Stem Cell Transplantation Outcomes in AML Patients

Use of T-Cell Antibodies for Donor Dosaging in a Canine Model of in utero Hematopoietic Stem Cell Transplantation

Contact Info

Product

Resources

About